PT3978074T - Terlipressina para tratamento da síndrome hepatorrenal de tipo 1 - Google Patents

Terlipressina para tratamento da síndrome hepatorrenal de tipo 1

Info

Publication number
PT3978074T
PT3978074T PT212057525T PT21205752T PT3978074T PT 3978074 T PT3978074 T PT 3978074T PT 212057525 T PT212057525 T PT 212057525T PT 21205752 T PT21205752 T PT 21205752T PT 3978074 T PT3978074 T PT 3978074T
Authority
PT
Portugal
Prior art keywords
treating patients
syndrome type
hepatorenal syndrome
hepatorenal
type
Prior art date
Application number
PT212057525T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Mallinckrodt Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Pharmaceuticals Ireland Ltd filed Critical Mallinckrodt Pharmaceuticals Ireland Ltd
Publication of PT3978074T publication Critical patent/PT3978074T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/024—Measuring pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1024—Counting particles by non-optical means

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Physiology (AREA)
  • Medical Informatics (AREA)
  • Ecology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
PT212057525T 2014-10-24 2015-10-22 Terlipressina para tratamento da síndrome hepatorrenal de tipo 1 PT3978074T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068357P 2014-10-24 2014-10-24
US201562151384P 2015-04-22 2015-04-22

Publications (1)

Publication Number Publication Date
PT3978074T true PT3978074T (pt) 2024-05-13

Family

ID=54478246

Family Applications (2)

Application Number Title Priority Date Filing Date
PT212057525T PT3978074T (pt) 2014-10-24 2015-10-22 Terlipressina para tratamento da síndrome hepatorrenal de tipo 1
PT157914300T PT3209317T (pt) 2014-10-24 2015-10-22 Terlipressina para tratamento da síndrome hepatorrenal de tipo 1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT157914300T PT3209317T (pt) 2014-10-24 2015-10-22 Terlipressina para tratamento da síndrome hepatorrenal de tipo 1

Country Status (15)

Country Link
US (2) US10335452B2 (enExample)
EP (3) EP3981420A1 (enExample)
JP (4) JP6673915B2 (enExample)
CN (2) CN107206049B (enExample)
AU (1) AU2015335855A1 (enExample)
CA (1) CA2965325A1 (enExample)
DK (2) DK3209317T3 (enExample)
ES (2) ES2904492T3 (enExample)
FI (1) FI3978074T3 (enExample)
HR (1) HRP20220225T1 (enExample)
HU (1) HUE058066T2 (enExample)
PL (2) PL3209317T3 (enExample)
PT (2) PT3978074T (enExample)
SI (1) SI3209317T1 (enExample)
WO (1) WO2016065117A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170929T1 (hr) 2008-09-17 2017-09-22 Chiasma Inc. Farmaceutski pripravci i odgovarajući postupci za isporuku
US20200046798A1 (en) * 2014-10-24 2020-02-13 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
US20210290725A1 (en) * 2014-10-24 2021-09-23 Mallinckrodt Pharmaceuticals Ireland Limited Method of treating patients with hepatorenal syndrome type 1
JP6673915B2 (ja) * 2014-10-24 2020-03-25 マリンクロット ホスピタル プロダクツ アイピー リミテッド １型肝腎症候群患者の治療方法
EP3528828B1 (en) * 2016-10-21 2025-01-29 Amryt Endo, Inc. Terlipressin composition for use in treating ascites
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN110251469B (zh) * 2019-07-31 2021-11-09 南京康舟医药科技有限公司 一种醋酸特利加压素制剂及其制备方法
WO2021084483A1 (en) * 2019-10-30 2021-05-06 Mallinckrodt Hospital Products IP Unlimited Company Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure
WO2023183339A1 (en) * 2022-03-22 2023-09-28 Ocelot Bio, Inc. Selective vasopressin receptor agonist for end-stage liver disease
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GB0617581D0 (en) * 2006-09-07 2006-10-18 Ucl Business Plc Biomarkers for assessing liver function
US20080221551A1 (en) * 2007-03-09 2008-09-11 Flowmedica, Inc. Acute kidney injury treatment systems and methods
US9050286B2 (en) 2007-08-14 2015-06-09 Ferring B.V. Use of peptidic vasopression receptor agonists
EP2913676A1 (en) * 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2661310T3 (es) 2009-03-09 2018-03-28 Bioatla, Llc Proteínas mirac
AU2010258888B2 (en) 2009-06-08 2014-08-07 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
AU2011279144A1 (en) * 2010-07-14 2013-01-24 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-A2 receptor antagonists
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
CN103254295A (zh) * 2013-05-31 2013-08-21 青岛国大生物制药股份有限公司 特利加压素的制备方法
JP6673915B2 (ja) * 2014-10-24 2020-03-25 マリンクロット ホスピタル プロダクツ アイピー リミテッド １型肝腎症候群患者の治療方法
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Also Published As

Publication number Publication date
JP6989571B2 (ja) 2022-01-05
JP2021155433A (ja) 2021-10-07
DK3209317T3 (da) 2022-02-07
US20190328831A1 (en) 2019-10-31
EP3209317B1 (en) 2021-12-08
US20160113994A1 (en) 2016-04-28
CN114028536B (zh) 2024-07-09
SI3209317T1 (sl) 2022-05-31
US10335452B2 (en) 2019-07-02
ES2904492T3 (es) 2022-04-05
CA2965325A1 (en) 2016-04-28
JP2017534618A (ja) 2017-11-24
JP2022171795A (ja) 2022-11-11
CN107206049A (zh) 2017-09-26
JP7346494B2 (ja) 2023-09-19
AU2015335855A1 (en) 2017-05-18
FI3978074T3 (fi) 2024-05-20
CN114028536A (zh) 2022-02-11
CN107206049B (zh) 2021-12-07
JP2019199485A (ja) 2019-11-21
WO2016065117A1 (en) 2016-04-28
EP3209317A1 (en) 2017-08-30
DK3978074T3 (da) 2024-05-13
EP3981420A1 (en) 2022-04-13
EP3978074B1 (en) 2024-03-06
HUE058066T2 (hu) 2022-06-28
HRP20220225T1 (hr) 2022-04-29
JP6673915B2 (ja) 2020-03-25
EP3978074A1 (en) 2022-04-06
PL3209317T3 (pl) 2022-05-23
ES2987577T3 (es) 2024-11-15
PT3209317T (pt) 2022-01-19
PL3978074T3 (pl) 2024-08-12

Similar Documents

Publication Publication Date Title
IL279627A (en) A method for treating depression
PT3978074T (pt) Terlipressina para tratamento da síndrome hepatorrenal de tipo 1
ZA201706059B (en) Method of treatment with tradipitant
PL3169362T3 (pl) Sposoby leczenia pacjentów wysokiego ryzyka sercowo-naczyniowego z hipercholesterolemią
IL248856A0 (en) New treatment
ZA201700416B (en) Methods for treating or preventing ophthalmological conditions
IL252111A0 (en) Methods for treating patients with Prader-Willi syndrome or Smith-Magnis syndrome
GB201410116D0 (en) Method of treatment
HUE065829T2 (hu) Eljárás Prader-Willi szindróma kezelésére
IL254825A0 (en) Methods of treatment with Tesalisib
IL253028A0 (en) treatment method
PL3234386T3 (pl) Element ślizgowy i sposób jego wytwarzania
PL3131549T3 (pl) Sposób leczenia zaburzeń ruchowych przy użyciu befiradolu
SG11201706885RA (en) Novel treatment method
GB201512139D0 (en) Methods of treatment
IL250083A0 (en) Treatment methods for patients with hypercholesterolemia and high cardiovascular risk
GB201421980D0 (en) Method of treatment
GB201421982D0 (en) Method of treatment
GB201415331D0 (en) Method of treatment
GB201414780D0 (en) Method Of Treatment
GB201417719D0 (en) New treatment
GB201408434D0 (en) Step treatment
GB201408384D0 (en) New treatment